Affiliations 

  • 1 University of Santo Tomas Hospital, Manila, Philippines
  • 2 Asian Heart & Vascular Centre, Singapore, Singapore
  • 3 University Putra Malaysia, Serdang, Malaysia
  • 4 Thomson Hospital Kota Damansara, Petaling Jaya, Malaysia
  • 5 Raffles Hospital, Singapore, Singapore
  • 6 de La Salle Medical and Health Sciences Institute, Dasmarinas Cavite, Philippines
  • 7 St Luke's Medical Center, Quezon City, Philippines
  • 8 Menarini Asia-Pacific Pte Ltd, Singapore, Singapore
Drugs Context, 2024;13.
PMID: 39165614 DOI: 10.7573/dic.2024-5-5

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.